Streetbeat News

CTNM

Contineum Therapeutics Inc.

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

13.68

Mkt cap

362M

Volume

171K

High

14.04

P/E Ratio

-38.97

52-wk high

22.00

Low

12.95

Div yield

N/A

52-wk low

12.33

Baird has initiated coverage on Contineum Therapeutics with an Outperform rating and set a price target of $32.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 9:21 am

RBC Capital analyst Brian Abrahams maintains an Outperform rating on Contineum Therapeutics (NASDAQ:CTNM) and raises the price target from $30 to $32.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 3:26 pm

Contineum Therapeutics shares are trading lower after the company reported worse-than-expected Q2 adjusted EPS results.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 3:20 pm

Contineum Therapeutics (NASDAQ:CTNM) reported a Q2 adjusted loss of $(0.39) per share, missing the analyst consensus estimate of $(0.35) by 11.43%. This represents a 146.43% decrease from the earnings of $0.84 per share in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:39 pm

Contineum Therapeutics (NASDAQ:CTNM) announced the publication of preclinical data on PIPE-307, a selective M1 receptor inhibitor for relapse-remitting multiple sclerosis, in the Proceedings of the National Academy of Sciences. The data suggest PIPE-307 could be a first-in-class treatment.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:07 pm

Contineum Therapeutics reported a Q3 EPS of $(3.55) and a cash position of $117.9 million.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 8:26 pm

RBC Capital analyst Brian Abrahams initiates coverage on Contineum Therapeutics (NASDAQ:CTNM) with an Outperform rating and a price target of $30.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 9:44 am

Stifel analyst Paul Matteis initiates coverage on Contineum Therapeutics (NASDAQ:CTNM) with a Buy rating and a price target of $29.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 9:20 am

Morgan Stanley has initiated coverage on Contineum Therapeutics (CTNM) with an Overweight rating and set a price target of $25. This move by a major financial institution could signal confidence in CTNM's future performance.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 9:15 am

Skillsoft Corp. shares fell by 26.7% after reporting mixed Q4 results and lower-than-expected FY25 revenue guidance. Other stocks moved significantly in Tuesday's session, with notable gainers including WiSA Technologies and Palisade Bio, and losers like Barnes & Noble Education and Calidi Biotherapeutics.

Portfolio Pulse from Avi Kapoor

April 16, 2024 | 6:17 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.